| Autor: |
van der Straten L; Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands. l.vanderstraten@iknl.nl.; Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, The Netherlands. l.vanderstraten@iknl.nl., Kater AP; Amsterdam UMC, Department of Hematology, Cancer Center Amsterdam, University of Amsterdam, Amsterdam, The Netherlands., Doorduijn JK; Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., van den Broek EC; PALGA Foundation, Houten, The Netherlands., Posthuma EFM; Department of Internal Medicine, Reinier de Graaf Hospital, Delft, The Netherlands.; Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands., Dinmohamed AG; Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands.; Amsterdam UMC, Department of Hematology, Cancer Center Amsterdam, University of Amsterdam, Amsterdam, The Netherlands.; Department of Public Health, Erasmus University Medical Center, Rotterdam, The Netherlands., Levin MD; Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, The Netherlands. |
| Abstrakt: |
Rituximab-containing chemotherapy remains a viable frontline treatment option for patients with chronic lymphocytic leukemia (CLL) in the era of novel agents. However, its effectiveness in the second-line setting-in relation to previous rituximab exposure in first-line-has hardly been evaluated in a population-based setting. Therefore, in this comprehensive, population-based study, we assessed the impact of first-line treatment with rituximab-containing chemotherapy on the effectiveness of second-line treatment with rituximab-containing chemotherapy. We selected all 1735 patients diagnosed with CLL between 2004 and 2010 from the Dutch Population-based HAematological Registry for Observational Studies (PHAROS). The primary endpoint was treatment-free survival (TFS). First- and second-line treatment was instituted in 663 (38%) and 284 (43%) patients, respectively. In first line, the median TFS was 19.7 and 67.1 months for chemotherapy without (n = 445; 67%) and with rituximab (n = 218; 33%), respectively (adjusted hazard ratio [HR adjusted ], 0.83; P = 0.031). The median TFS among recipients of second-line chemotherapy without (n = 165; 57%) and with rituximab (n = 121; 42%) was 15.0 and 15.3 months, respectively (HR adjusted , 0.93; P = 0.614). Of the 121 patients who received rituximab-containing chemotherapy in second-line, 89 (74%) and 32 (26%) received first-line chemotherapy without and with rituximab, respectively. Median TFS in these two treatment groups was 18.3 and 12.1 months, respectively (HR adjusted , 1.71; P = 0.060). Collectively, in this population-based study, the effectiveness of first-line treatment with rituximab-containing chemotherapy was less pronounced in second-line treatment. The hampered effectiveness of rituximab-containing chemotherapy in second-line could not be explained by previous rituximab exposure. |
Full text from SpringerLink